VERASEAL SOLUTIONS FOR SEALANT, 80 MG/ML, 500 IU/ML [SIN16143P]
Active ingredients: HUMAN FIBRINOGEN | HUMAN THROMBIN
Last updated on 9 October 2026
Product Info
VERASEAL SOLUTIONS FOR SEALANT, 80 MG/ML, 500 IU/ML
[SIN16143P]
Product information
Active Ingredient and Strength | HUMAN FIBRINOGEN - 80 MG/ML |
Dosage Form | SOLUTION |
Manufacturer and Country | INSTITUTO GRIFOLS, S.A. - SPAIN |
Registration Number | SIN16143P |
Licence Holder | GRIFOLS ASIA PACIFIC PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | B02BC |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
Therapeutic indications
VeraSeal is indicated as supportive treatment in patients where standard surgical techniques are insufficient:
for improvement of haemostasis.
as suture support: in vascular surgery.
VeraSeal is indicated in all age groups.
Dosing
Posology and method of administration
The use of VeraSeal is restricted to experienced surgeons who have been trained in the use of this medicinal product.
Posology
The volume of VeraSeal to be applied and the frequency of application should always be oriented towards the underlying clinical needs for the patient.
The dose to be applied is governed by variables including, but not limited to, the type of surgical intervention, the size of the area and the mode of intended application, and the number of applications.
Application of the product must be individualised by the treating physician. In clinical trials, the individual dosages have typically ranged from 0.3 to 12 ml. For other procedures, larger volumes may be required.
The initial volume of the product to be applied at a chosen anatomic site or target surface area should be sufficient to entirely cover the intended application area. The application can be repeated, if necessary.
Paediatric population
The safety and efficacy of VeraSeal in children aged 0 to 18 years has been evaluated in a clinical study. Currently available data are described in section Pharmacodynamic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. Application of the product must be individualised by the treating physician. In the paediatric clinical trial, the individual dose ranged from 0.6 to 12 ml.
Method of administration
For epilesional use.
For instructions on preparation of the medicinal product before administration, see section Instructions for use, handling and disposal – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. The product should only be administered according to the instructions and with the devices recommended for this product (see section Instructions for use, handling and disposal – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Prior to applying VeraSeal, the surface area of the wound needs to be dried by standard techniques (e.g. intermittent application of compresses, swabs, use of suction devices).
For spray application, see sections Special warnings and precautions for use and Instructions for use, handling and disposal for specific recommendations on the required distance from tissue per surgical procedure – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Contraindications
Contraindications
VeraSeal must not be applied intravascularly.
Hypersensitivity to the active substance or to any of the excipients listed in section List of excipients – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
VeraSeal must not be used for the treatment of severe or brisk arterial bleeding.